15
Dec
How to Strip a Stock to Its Cash Bones
Filings first. Cash over stories. A repeatable way to read any company.
5 min read
Cash Flow Analysis
19
Nov
AbbVie: Boring Business, Beautiful Cash Flow
AbbVie survived the Humira patent cliff everyone feared. Now at single-digit P/E with $22B in free cash flow and a 3% yield, you're paying for pharma discipline while others chase biotech moonshots. Sometimes boring wins.
3 min read
12
Nov
Chevron: Built for Cash, Not Clicks
Chevron survived the Hess deal distraction. Now at $153 with 80% upstream margins and FCF covering dividends 1.7x, you're paying for discipline at 16.5× earnings. Guyana's $35 breakevens change everything. Target: $170 by 2027.
3 min read